Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Vector Type (Viral Vector, Non-Viral Vector), By Delivery Method (In-Vivo, Ex-Vivo), By Indication (Rare Diseases, Cancer, Neurological Diseases, Others), By Region, By Competition Forecast

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 6.01 Billion

CAGR (2023-2028)

9.26%

Fastest Growing Segment

Non-viral vectors

Largest Market

North America


Market Overview

Global Gene Therapy Market has valued at USD 6.01 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.26% through 2028. The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market’s growth during the forecast period. The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.

Key Market Drivers

Advancements in Genetic Research

The increasing understanding of the genetic basis of diseases has enabled scientists to identify specific genes responsible for various disorders. This knowledge is crucial for designing targeted gene therapies that can correct or replace defective genes, addressing the root cause of diseases. Genetic research has identified specific genetic mutations or abnormalities that contribute to various diseases, such as inherited genetic disorders and certain types of cancer. This has provided gene therapists with clear therapeutic targets, allowing them to develop more precise and effective treatments. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy. These techniques enable scientists to accurately and efficiently edit or modify genes, opening up new possibilities for treating genetic disorders. Genetic research has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup. This approach enhances the effectiveness of gene therapies by considering genetic variations that might affect treatment outcomes, leading to better patient responses and reduced adverse effects. Genetic research has facilitated the development of advanced delivery systems that help target specific tissues or cells with greater precision. This has improved the efficiency of gene therapy treatments, minimized off-target effects and enhancing therapeutic outcomes. The promising outcomes of genetic research have attracted substantial investment in the gene therapy sector. As the potential of gene therapies becomes more apparent, investors are more willing to fund research and development, driving innovation and market growth.

Rising Prevalence of Genetic Disorders

The increasing number of individuals diagnosed with genetic disorders highlights the unmet medical need for effective treatments. Conventional treatments for many genetic disorders often focus on managing symptoms rather than addressing the root cause. Gene therapy presents an opportunity to provide targeted and long-lasting solutions for these disorders. The growing prevalence of genetic disorders means that there is a larger patient population that could potentially benefit from gene therapy. This expanded patient pool translates to a higher demand for gene therapy treatments and a larger market opportunity. The rising prevalence of genetic disorders makes the gene therapy market more attractive to pharmaceutical companies, biotechnology firms, and investors. The potential for a sizable customer base and the ability to provide innovative solutions to unmet medical needs can drive increased investment and research in the field. The prevalence of genetic disorders provides ample opportunities for conducting clinical trials to test the safety and efficacy of gene therapy treatments. This contributes to the advancement of research and development in the gene therapy sector and supports the growth of the market. Genetic disorders are not limited to specific regions; they affect populations worldwide. This global reach provides gene therapy companies with opportunities to develop and market their treatments on a global scale, further contributing to market growth.

Collaborations and Partnerships

Gene therapy involves a multidisciplinary approach, including molecular biology, genetics, biotechnology, clinical research, and regulatory affairs. Collaborations bring together experts from different fields, allowing them to share knowledge, insights, and best practices. This collective expertise fosters innovation and drives the development of more advanced and effective gene therapies. Collaborative efforts can significantly speed up the research and development process. By combining resources, data, and technologies, researchers and companies can overcome challenges more efficiently, reducing the time required to bring new gene therapies from concept to clinical application. Partnerships provide access to specialized technologies and tools that may not be available within a single organization. This access can lead to breakthroughs in gene delivery systems, gene editing techniques, and other critical components of gene therapy development. Gene therapy manufacturing can be challenging due to the need for precise and consistent production processes. Partnerships can facilitate the development of scalable manufacturing techniques, ensuring the production of sufficient quantities of gene therapies for clinical trials and commercialization. Regulatory approval is a critical step in bringing gene therapies to market. Collaborations with regulatory experts and consultants can help navigate the complex regulatory landscape, ensuring that therapies meet safety and efficacy standards and gain timely approvals.

Download Free Sample Report

Key Market Challenges

Technical Complexity

Developing effective gene therapies requires a deep understanding of genetics, molecular biology, and complex cellular processes. The technical complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Getting therapeutic genes into target cells poses a significant challenge. Developing efficient and safe delivery systems, such as viral vectors or nanoparticles, requires extensive optimization and testing. Technical difficulties in achieving precise and controlled delivery can affect the success of gene therapies. The interactions between modified genes and the host organism can sometimes lead to unintended consequences. Technical complexities can make it difficult to predict the outcomes of gene therapies accurately, leading to safety concerns and regulatory challenges. Regulatory agencies require a high level of safety and efficacy data for gene therapy products due to their complexity and potential risks. Navigating the regulatory pathway for gene therapies can be challenging and time-consuming, hindering market growth. Manufacturing gene therapy products in a consistent and scalable manner is challenging due to the complexity of biological processes involved. Ensuring the quality, safety, and stability of gene therapies at a commercial scale can be technically demanding and expensive.

High Development Costs

Initial research to identify target genes, develop therapeutic constructs, and validate their efficacy in preclinical models can be expensive. This stage requires significant investment in laboratory resources, equipment, and skilled personnel. Conducting clinical trials is a critical step in the development of any medical intervention, including gene therapies. The cost of designing, executing, and monitoring clinical trials (Phase I to Phase III) can be substantial due to factors such as patient recruitment, regulatory compliance, data collection, and safety monitoring. Meeting regulatory requirements set by agencies such as the FDA and EMA demands rigorous testing, documentation, and quality control. The cost of compiling data and preparing submissions for regulatory approval can be significant. Developing consistent, high-quality gene therapy products for clinical trials and commercialization involves complex and costly manufacturing processes. Ensuring the scalability, stability, and safety of manufacturing adds to development expenses. Building a team of experts in gene therapy, molecular biology, clinical research, and regulatory affairs is essential for successful development. Attracting and retaining skilled professionals can be costly, especially given the specialized nature of the field. Cutting-edge technologies, such as gene editing tools and viral vectors, are crucial for developing advanced gene therapies. Acquiring and implementing these technologies requires substantial investments.

Key Market Trends

Expanding Therapeutic Targets

Identifying new therapeutic targets means gene therapy can be applied to a wider range of medical conditions beyond traditional monogenic disorders. This diversity includes complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare diseases, expanding the addressable patient population. The availability of gene therapies for multiple therapeutic targets attracts a larger patient base, driving market growth by increasing the potential customer pool and commercial opportunities. The discovery of new therapeutic targets stimulates research and development efforts by both established pharmaceutical companies and smaller biotechnology firms. This influx of investment fuels innovation and accelerates the development of gene therapies for various indications. Expanding therapeutic targets leads to a more diverse portfolio of clinical trials. This diversity enhances the clinical trial landscape, allowing researchers to explore different patient populations, endpoints, and treatment approaches, ultimately advancing the field. As gene therapies target a wider array of diseases, regulatory agencies may provide specialized pathways or guidelines for specific indications. This attention can expedite regulatory approval processes and facilitate market entry. The availability of gene therapies for more common and relatable diseases can increase public awareness and acceptance of the technology. Positive outcomes in well-known conditions can build trust and reduce skepticism. Expanding therapeutic targets can lead to collaborations between academic researchers, industry partners, and patient advocacy groups. Collaborations strengthen expertise, resources, and support networks, fostering innovation and growth. The potential for gene therapies to target various indications attracts diverse investors interested in contributing to the development of treatments for specific diseases, fostering a competitive market landscape.

Growing CRISPR-Based Therapies

CRISPR-Cas9 technology allows researchers to edit genes with unparalleled precision. This precision is crucial for correcting or modifying specific genetic mutations that underlie various diseases. The ability to target and modify genes accurately enhances the effectiveness and safety of gene therapies. CRISPR-Cas9 enables the modification of a wide range of genetic targets, from single nucleotide changes to larger genomic segments. This expands the potential applications of gene therapy to include a broader spectrum of genetic disorders, including both monogenic and complex conditions. The simplicity and accessibility of CRISPR technology have accelerated gene therapy research. Scientists can design and implement experiments more efficiently, leading to faster discoveries and a quicker translation of findings into potential therapies. CRISPR-based therapies contribute to a more diverse pipeline of potential treatments. As researchers explore new gene targets and develop innovative therapies, the gene therapy market gains momentum with a wider range of options. The precise nature of CRISPR-Cas9 editing can streamline the regulatory process by providing clear evidence of the intended genetic changes. This can facilitate faster approvals for clinical trials and eventual market entry. The accessibility of CRISPR technology has encouraged global collaboration among researchers, enabling the sharing of knowledge, techniques, and resources. This collaborative environment accelerates progress and drives market growth. The potential of CRISPR-based therapies has led to the establishment of new biotech companies dedicated to gene editing and gene therapy. This increased industry presence contributes to competition, innovation, and market expansion.

Segmental Insights

Vector Type Insights

Based on the Vector Type, the Non-Viral Vector segment is anticipated to witness substantial market growth throughout the forecast period. This growth can be attributed to multiple factors, such as Non-viral vectors typically have a lower risk of inducing immune responses compared to viral vectors. This enhanced safety profile reduces the likelihood of adverse effects and regulatory concerns, facilitating the development and approval of gene therapies. Non-viral vectors are less likely to integrate into the host genome, reducing the risk of insertional mutagenesis, a concern associated with certain viral vectors. This safety advantage supports long-term therapeutic applications. Non-viral vectors are less likely to provoke strong immune responses, enabling repeated administrations of gene therapies if necessary. This can be especially valuable for chronic conditions that require multiple treatments. Non-viral vectors often have simpler manufacturing processes than viral vectors, potentially reducing production costs and enabling more scalable manufacturing for clinical and commercial purposes. The safety advantages of non-viral vectors can lead to smoother regulatory pathways, facilitating faster approvals and reducing hurdles for clinical development and market entry. The emergence of non-viral vector technologies attracts a broader range of industry players, including biotechnology companies and academic institutions. This diversification drives competition, innovation, and market growth.

Delivery Method Insights

Based on the Delivery Method segment, the In-Vivo segment has been the dominant force in the market. In vivo gene therapy avoids the need for invasive procedures such as surgical implantation. This non-invasive nature makes it more acceptable to patients and reduces the risks associated with surgical interventions. In vivo gene therapy can be administered systemically, making it accessible to a broader range of patients. This approach is particularly beneficial for patients with diseases affecting multiple organs or tissues. In vivo gene therapy has the potential to affect multiple target cells or tissues throughout the body. This systemic effect is advantageous for conditions that involve widespread genetic abnormalities or diseases affecting multiple organs. Successful in vivo gene therapy can result in long-lasting effects, as the introduced genetic material continues to express itself within the patient's body. In vivo gene therapy can address a wide range of therapeutic targets, from monogenic disorders to complex diseases like cancer, cardiovascular diseases, and neurodegenerative conditions. The non-invasive nature and systemic effect of in vivo gene therapy can positively influence patient acceptance, making clinical trial recruitment and market adoption smoother. The versatility of in vivo gene therapy allows for applications in a variety of medical fields, attracting a wider range of researchers, developers, and companies to the gene therapy market.


Download Free Sample Report

Regional Insights

North America, specifically the Gene Therapy Market, dominated the market in 2022, primarily due to North America, particularly the United States, has a robust research and innovation ecosystem that includes top universities, research institutions, and biotechnology companies. This environment fosters cutting-edge gene therapy research and development. North America attracts significant investments from both private and public sources into gene therapy research and clinical trials. Venture capital firms, pharmaceutical companies, and government grants contribute to funding the advancement of gene therapies. The region boasts well-established clinical trial infrastructure, including experienced investigators, specialized medical centers, and patient recruitment networks. This infrastructure accelerates the progress of clinical trials and speeds up the translation of research into therapies. North America is home to numerous biotechnology companies focused on gene therapy. These companies are at the forefront of developing innovative therapies and technologies, contributing to the overall market growth. The advanced healthcare infrastructure and access to specialized medical expertise in North America provide a conducive environment for the clinical application and adoption of gene therapies.

Recent Developments

  • In June 2023, Sangamo Therapeutics Inc. entered into a licensed agreement with Voyager Therapeutics Inc. for the development of the epigenetic regulation treatment, a gene therapy, for treating prion disease.
  • In May 2023, Oxford BioMedica Plc launched the TetraVectaTM System which is the 4th generation lentiviral vector delivery system. It is useful for gene therapy for delivering therapeutic genes into target cells.
  • In December 2022, the collaboration between Cellectis SA and Mayflower Bioventures resulted in the launch of Primera Therapeutics. The purpose was to develop gene editing therapies for the treatment of mitochondrial disease.
  • In June 2022, the alliance between Bristol-Myers Squibb Company and Immatics NV expanded for the development of multiple allogenic off the shelf TCR-T, and CAR-T programs. Both these are gene therapy programs that modify a patient’s T cells to target and attack cancer cells.
  • In January 2022, Novartis AG collaborated with Alnylam to explore target therapies for restoring liver function. In this collaboration, Novartis utilized Alnylam’s siRNA technology which is a gene therapy to develop a treatment for the regrowth of functional livers.

Key Market Players

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi-Aventis
  • Applied genetic technologies corporation.
  • F. Hoffmann-la roche ltd.
  • Bluebird bio, inc.
  • Novartis ag
  • Uniqure n.v.

 By Vector Type

By Delivery Method

By Indication

By Region

Viral Vector

Non-Viral Vector

In-Vivo

Ex-Vivo

Rare Diseases

Cancer

Neurological Diseases

Others

North America

Europe

Asia Pacific

South America

Middle East & Africa

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Gene Therapy Market, By Vector Type:

o   Viral Vector

o   Non-Viral Vector

  • Gene Therapy Market, By Delivery Method:

o   In-Vivo

o   Ex-Vivo

  • Gene Therapy Market, By Indication:

o   Rare Diseases

o   Cancer

o   Neurological Diseases

o   Others  

  • Gene Therapy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Gene Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Clinical Trial Analysis

             4.1 Ongoing Clinical Trials

             4.2 Completed Clinical Trials

             4.3 Terminated Clinical Trials

             4.4 Breakdown of Pipeline, By Development Phase

            4.5 Breakdown of Pipeline, By Status

            4.6 Breakdown of Pipeline, By Study Type

            4.7 Breakdown of Pipeline, By Region

            4.8 Clinical Trials Heat Map

5.    Voice of Customer

6.    Global Gene Therapy Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Vector Type (Viral Vector, Non-Viral Vector)

5.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)

5.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)

6.2.2.    By Delivery Method (In-Vivo, Ex-Vivo)

6.2.3.    By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)

6.2.4.    By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

6.2.5.    By Company (2022)

6.3.  Market Map

5.3.1 By Vector Type

5.3.2 By Delivery Method

5.3.3 By Indication

5.3.4 By Region

7.    North America Gene Therapy Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Vector Type (Viral Vector, Non-Viral Vector)

7.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)

7.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)

7.2.2.    By Delivery Method (In-Vivo, Ex-Vivo)

7.2.3.    By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)

7.2.4.    By Country

7.3.  North America: Country Analysis

7.3.1.    United States Gene Therapy Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Vector Type

7.3.1.2.2.            By Delivery Method

7.3.1.2.3.            By Indication

7.3.2.    Canada Gene Therapy Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Vector Type

7.3.2.2.2.            By Delivery Method

7.3.2.2.3.            By Indication

7.3.3.    Mexico Gene Therapy Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.            By Vector Type

7.3.3.2.2.            By Delivery Method

7.3.3.2.3.            By Indication

8.    Europe Gene Therapy Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Vector Type (Viral Vector, Non-Viral Vector)

8.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)

8.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)

8.2.2.    By Delivery Method (In-Vivo, Ex-Vivo)

8.2.3.    By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)

8.2.4.    By Country

8.3.  Europe: Country Analysis

8.3.1.    France Gene Therapy Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Vector Type

8.3.1.2.2.            By Delivery Method

8.3.1.2.3.            By Indication

8.3.2.    Germany Gene Therapy Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Vector Type

8.3.2.2.2.            By Delivery Method

8.3.2.2.3.            By Indication

8.3.3.    United Kingdom Gene Therapy Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Vector Type

8.3.3.2.2.            By Delivery Method

8.3.3.2.3.            By Indication

8.3.4.    Italy Gene Therapy Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Vector Type

8.3.4.2.2.            By Delivery Method

8.3.4.2.3.            By Indication

8.3.5.    Spain Gene Therapy Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Vector Type

8.3.5.2.2.            By Delivery Method

8.3.5.2.3.            By Indication

9.    Asia-Pacific Gene Therapy Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Vector Type (Viral Vector, Non-Viral Vector)

9.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)

9.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)

9.2.2.    By Delivery Method (In-Vivo, Ex-Vivo)

9.2.3.    By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)

9.2.4.    By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.    China Gene Therapy Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Vector Type

9.3.1.2.2.            By Delivery Method

9.3.1.2.3.            By Indication

9.3.2.    India Gene Therapy Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Vector Type

9.3.2.2.2.            By Delivery Method

9.3.2.2.3.            By Indication

9.3.3.    Japan Gene Therapy Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Vector Type

9.3.3.2.2.            By Delivery Method

9.3.3.2.3.            By Indication

9.3.4.    South Korea Gene Therapy Market Outlook

9.3.4.1.        Market Size & Forecast

9.3.4.1.1.            By Value

9.3.4.2.        Market Share & Forecast

9.3.4.2.1.            By Vector Type

9.3.4.2.2.            By Delivery Method

9.3.4.2.3.            By Indication

9.3.5.    Australia Gene Therapy Market Outlook

9.3.5.1.        Market Size & Forecast

9.3.5.1.1.            By Value

9.3.5.2.        Market Share & Forecast

9.3.5.2.1.            By Vector Type

9.3.5.2.2.            By Delivery Method

9.3.5.2.3.            By Indication

10.  South America Gene Therapy Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)

10.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)

10.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)

10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)

10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)

10.2.4. By Country

10.3.   South America: Country Analysis

10.3.1. Brazil Gene Therapy Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Vector Type

10.3.1.2.2.         By Delivery Method

10.3.1.2.3.         By Indication

10.3.2. Argentina Gene Therapy Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Vector Type

10.3.2.2.2.         By Delivery Method

10.3.2.2.3.         By Indication

10.3.3. Colombia Gene Therapy Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Vector Type

10.3.3.2.2.         By Delivery Method

10.3.3.2.3.         By Indication

11.  Middle East and Africa Gene Therapy Market Outlook

11.1.   Market Size & Forecast         

11.1.1. By Value

11.2.   Market Share & Forecast

11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)

11.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)

11.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)

11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)

11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)

11.2.4. By Country

11.3.   MEA: Country Analysis

11.3.1. South Africa Gene Therapy Market Outlook

11.3.1.1.     Market Size & Forecast

11.3.1.1.1.         By Value

11.3.1.2.     Market Share & Forecast

11.3.1.2.1.         By Vector Type

11.3.1.2.2.         By Delivery Method

11.3.1.2.3.         By Indication

11.3.2. Saudi Arabia Gene Therapy Market Outlook

11.3.2.1.     Market Size & Forecast

11.3.2.1.1.         By Value

11.3.2.2.     Market Share & Forecast

11.3.2.2.1.         By Vector Type

11.3.2.2.2.         By Delivery Method

11.3.2.2.3.         By Indication

11.3.3. UAE Gene Therapy Market Outlook

11.3.3.1.     Market Size & Forecast

11.3.3.1.1.         By Value

11.3.3.2.     Market Share & Forecast

11.3.3.2.1.         By Vector Type

11.3.3.2.2.         By Delivery Method

11.3.3.2.3.         By Indication

12.  Market Dynamics

12.1.   Drivers

12.2.   Challenges

13.  Market Trends & Developments

13.1.   Recent Development

13.2.   Mergers & Acquisitions

13.3.   Product Launches

14.  Global Gene Therapy Market: SWOT Analysis

15.  Funding Analysis

16.  Porter’s Five Forces Analysis

16.1.   Competition in the Industry

16.2.   Potential of New Entrants

16.3.   Power of Suppliers

16.4.   Power of Customers

16.5.   Threat of Substitute Products

17.  Competitive Landscape

17.1.   Business Overview

17.2.   Product Offerings

17.3.   Recent Developments

17.4.   Financials (As Reported)

17.5.   Key Personnel

17.6.   SWOT Analysis

15.6.1    REGENXBIO Inc.

15.6.2    Oxford Biomedica PLC.

15.6.3    Voyager Therapeutics Inc.

15.6.4    Human Stem Cells Institute

15.6.5    Dimension Therapeutics, Inc.

15.6.6    Bristol-Myers Squibb Company

15.6.7    Sanofi-Aventis

15.6.8    Applied genetic technologies corporation.

15.6.9    F. Hoffmann-la Roche ltd.

15.6.10  Bluebird bio, Inc.

15.6.11  Novartis AG

15.6.12  Uniqure N.V.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Gene Therapy Market was estimated to be USD 6.01 Billion in 2022.

down-arrow

The Cancer segment demonstrated significant dominance in 2022, primarily driven by Due to the approval of an increasing number of gene therapies for cancer therapy and the rising incidence of hematologic tumors, the oncological disorders are boosting the market growth.

down-arrow

North America emerged as the dominant market in 2022, capturing a significant revenue share. Several government organizations are supporting research campaigns around the country, owing to the robust regulatory framework for cellular treatment development and the substantial presence of biopharmaceutical businesses, these are also likely to fuel the market growth.

down-arrow

Increased investment in research and development by government and private organizations and rapid technological advancements in cellular and molecular biology in genomics research are the major drivers for the Global Gene Therapy Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Gene Therapy Market to be dominated by Non-Viral Vectors through 2028

Oct, 2023

Increase in the number of cases of cancer and other chronic diseases is expected to drive the Global Gene Therapy Market growth in the forecast period, 2024-2028.

Why Choose Us